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Mutations in PINK1 and Parkin result in autosomal recessive Parkinson’s 
disease (PD). Cell culture and   studies have elaborated the PINK1
dependent regulation of Parkin and defined how this dyad orchestrates the 
elimination of damaged mitochondria  mitophagy. PINK1 phosphorylates 
ubiquitin at Serine 65 (Ser65) and Parkin at an equivalent Ser65 residue 
located within its Nterminal ubiquitinlike domain resulting in activation, 
however the physiological significance of Parkin Ser65 phosphorylation  
in mammalsremains unknown. To address this, we generated a 	
S65A 
knockin mouse model. We observe endogenous ParkinSer65 phosphorylation 
and activation in mature primary neurons following mitochondrial 
depolarisation and reveal this is disrupted in 	
S65A/S65A neurons. 
Phenotypically, 	
S65A/S65A mice exhibit selective motor dysfunction in the 
absence of any overt neurodegeneration or alterations in nigrostriatal 
mitophagy. The clinical relevance of our findings are substantiated by the 
discovery of homozygous PARKIN (	) p.S65N mutations in two 
unrelated patients with PD. Moreover, biochemical and structural analysis 
demonstrate that the ParkinS65N mutant is pathogenic and cannot be activated 
by PINK1. Our findings highlight the central role of Parkin Ser65 
phosphorylation in health and disease.  
 
Autophagy, Mitochondria, Mitophagy, QC, neurodegeneration, Parkin 
Parkinson’s disease, PINK1, Striatum, Ubiquitin 
 !"

Role of Parkin phosphorylation  
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Mutations in genes encoding PTENinduced kinase 1 (PINK1) (human 
	) and the ubiquitin E3 ligase Parkin (human 	) are causal for 
earlyonset Parkinson’s disease (PD) with clinically indistinguishable 
phenotypes (Kitada, Asakawa et al. 1998, Valente, AbouSleiman et al. 2004). 
Patients typically exhibit a motor syndrome associated with nigrostriatal 
pathology that can occur in the absence or presence of Lewy body inclusions 
(Walden and Muqit 2017). Under specific conditions of mitotoxic stress in 
cultured cells, PINK1 and Parkin converge in a common signal transduction 
pathway to eliminate damaged mitochondria  autophagy, known as 
mitophagy (Pickrell and Youle 2015, McWilliams and Muqit 2017, Harper, 
Ordureau et al. 2018). Over the last decade, this pathway has been 
intensively studied to understand the mechanisms by which these enzymes 
regulate mitochondrial homeostasis (Pickrell and Youle 2015, McWilliams and 
Muqit 2017, Harper, Ordureau et al. 2018). In cell culture, PINK1 is activated 
upon mitochondrial depolarisation that can be induced by uncouplers or 
inhibitors of complex III/V e.g. Antimycin A/Oligomycin (A/O). This results in 
the recruitment and activation of Parkin at the outer mitochondrial membrane 
(OMM) (Pickrell and Youle 2015, McWilliams and Muqit 2017, Harper, 
Ordureau et al. 2018). PINK1 directly phosphorylates Parkin at a highly 
conserved Serine 65 (Ser65) residue within its Nterminal ubiquitinlike domain 
(Ubl), as well as the equivalent Ser65 residue of ubiquitin (Ub). 
Phosphorylation of both Parkin and ubiquitin is required for maximal activation 
of Parkin E3 ligase activity (Kane, Lazarou et al. 2014, Kazlauskaite, Kelly et 
al. 2014, Kazlauskaite, Kondapalli et al. 2014, Koyano, Okatsu et al. 2014, 
Kazlauskaite, MartinezTorres et al. 2015). Upon activation, Parkin 
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ubiquitylates multiple substrates at the OMM leading to both   
assembly and elongation of existing ubiquitin chains that are in turn, 
phosphorylated by PINK1. Together, this generates a feedforward 
enhancement of Parkin activation and mitochondrial ubiquitylation that heralds 
the recruitment of selective autophagy adaptors necessary for the completion 
of mitophagy (Ordureau, Sarraf et al. 2014, Heo, Ordureau et al. 2015, 
Lazarou, Sliter et al. 2015, Ordureau, Heo et al. 2015). 
Our present understanding of PINK1dependent Parkin activation is largely 
predicated on  observations and cell culture studies, which often exploit 
the overexpression of exogenous Parkin and/or PINK1 at supraphysiological 
levels (Pickrell and Youle 2015, McWilliams and Muqit 2017, Harper, 
Ordureau et al. 2018). These include the previous demonstration that Parkin 
Ser65 phosphorylation may not be essential for its complete E3 ligase activity 
(Kazlauskaite, Kelly et al. 2014, Ordureau, Sarraf et al. 2014), or its 
depolarisationinduced mitochondrial translocation (Kane, Lazarou et al. 2014, 
Koyano, Okatsu et al. 2014). Despite a concerted body of work in this area 
from many laboratories, the physiological significance of Parkin Ser65 
phosphorylation by PINK1   remains largely enigmatic. Furthermore, 
additional substrates for PINK1 have been widely reported (Truban, Hou et al. 
2017) but to date, it is unknown whether inactivation of PINK1dependent 
substrate phosphorylation is sufficient to recapitulate neurodegeneration 
. Models of germline 	
 knockout mice only exhibit mild phenotypes, 
with chronic mitotoxicity or extreme stress required to elicit PDrelevant 
neurological phenotypes (Goldberg, Fleming et al. 2003, Itier, Ibanez et al. 
2003, Kitada, Pisani et al. 2009, Damiano, Gautier et al. 2014, Pickrell, Huang 
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et al. 2015). To test the hypothesis that Parkin Ser65 phosphorylation is critical 
for its activation  , we generated a 	
 Ser65Ala knockin mouse 
(	
S65A/S65A)and performed an extensive multiparametric characterisation 
of this model. We demonstrate that phosphorylation of Ser65 is critical for 
endogenous Parkin activation and Ser65phosphorylated ubiquitin (hereafter 
referred to as phosphoubiquitin) accumulation in primary cells, including 
neurons. Loss of endogenous Parkin Ser65 phosphorylation and activity 
results in selective locomotor impairments, accompanied by a mild striatal
specific mitochondrial defect . Furthermore, crossing our 	
S65A/S65A 
mice with the recently described QC mitophagy reporter model 
(McWilliams, Prescott et al. 2016), revealed that basal mitophagy in 
nigrostriatal dopamine neurons proceeds normally in 	
S65A/S65A mice, 
suggesting that basal mitophagy here proceeds independently of Parkin E3 
ligase activity. The pathophysiological significance of Parkin Ser65 
phosphorylation in mammals is ultimately substantiated by the clinical 
discovery of two unrelated patients with relatively earlyonset PD harbouring a 
homozygous 	 Ser65Asn (ParkinS65N) mutation. Characterisation of 
patientderived primary cells demonstrates that the Parkin S65N mutation is 
inactive, suggesting that the loss of PINK1dependent Parkin Ser65 
phosphorylation and subsequent inactivation in humans is sufficient to cause 
familial PD. Taken together, our data demonstrates that the phosphorylation 
state of Parkin at Ser65 is crucial for mitochondrial integrity and human 
nigrostriatal function. 
$%&"
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To test the hypothesis that Parkin Ser65 phosphorylation is central to Parkin 
activation and neuronal homeostasis , we generated a knockin mouse 
model, in which the codon encoding Parkin Ser65 was altered by homologous 
recombination to alanine to prevent Parkin protein phosphorylation by PINK1 
(Figure 1A). Homozygous 	
S65A/S65A mice were born at expected 
Mendelian frequencies and wildtype and mutant mice were indistinguishable 
in terms of gross measures of growth, weight and development (data not 
shown). 
The expression and stability of the endogenous mutant ParkinS65A protein in 
	
S65A/S65A mice was comparable to wildtype mice across all brain regions 
(olfactory bulb, cortex, thalamus, striatum, hippocampus, ventral midbrain, 
cerebellum, brainstem and spinal cord) and extraneural tissues (heart, 
spleen, lung and pancreas) (Figure 1B and Supplementary Figure 1). To 
assess how the S65A mutation affects Parkin ubiquitin E3 ligase activity, we 
undertook biochemical analysis of endogenous substrate ubiquitylation in 
cultured primary neurons. Given the availability of reliable reagents and 
building upon our previous work in this area (Kazlauskaite, MartinezTorres et 
al. 2015, Lai, Kondapalli et al. 2015), we focused our attention on the 
mitochondrial Fe/S domaincontaining protein CISD1, a welldescribed Parkin 
substrate, in addition to monitoring endogenous Parkin Ser65 phosphorylation. 
We have previously observed that endogenous Parkin is expressed at low 
levels in mouse embryonic fibroblasts (MEFs) which limits the robust 
detection of endogenous Parkin signalling (Lai, Kondapalli et al. 2015). 
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However, in primary cortical neuron cultures established from E16.5 mouse 
embryos cultured to maturity for 21 days   (DIV), endogenous Parkin 
phosphorylation and substrate ubiquitylation are reliably detectable after 
combined Antimycin A and Oligomycin stimulation (inhibition of respiratory 
chain enzyme complex II/III and ATP synthase respectively; hereafter referred 
to as A/O) (Barini, Miccoli et al. 2018). Upon treatment of mature (21 DIV) 
cortical neurons with A/O for three hours (3 h), we observed complete loss of 
CISD1 ubiquitylation in 	
S65A/S65A neurons compared to wildtype, as 
measured by antiCISD1 immunoblotting (Figure 1C). Immunoblot analysis 
using antiphosphoSer65 Parkin antibodies confirmed the loss of Parkin 
phosphorylation at Ser65 in mutant neurons (Figure 1C). We also assessed 
endogenous ubiquitylation status of additional Parkin substrates including 
Mitofusin2, Miro2 and VDAC1 however, we were unable to detect robust 
signal in neurons in whole cell lysates or following HALOUbiquilin1 UBA
domain tetramer (UBAUBQLN1) TUBEpulldown experiments (Supplementary 
Figure 2). We predict this may be due to their low stoichiometry of 
ubiquitylation, demonstrated recently in human neurons by quantitative mass 
spectrometry (Ordureau, Paulo et al. 2018). We next asked whether loss of 
Parkin activity in 	
S65A/S65A neurons influenced the PINK1dependent 
phosphorylation of ubiquitin at Ser65 and its subsequent accumulation. We 
undertook comparative biochemical analyses of mature primary neuron 
cultures established from homozygous 	
S65A/S65A, 	
 knockout, and
	
 knockout mice with their respective corresponding wildtype littermate 
controls. Consistent with previous studies in proliferating cell lines, we 
observed complete loss of Ser65phosphorylated ubiquitin (phosphoubiquitin) 
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and CISD1 ubiquitylation in 	
 knockout neurons, as judged by 
immunoblotting of HALOUBAUBQLN1 pulldowns with antiphosphoSer65 
ubiquitin and antiCISD1 antibodies (Figure 2). Strikingly we did not observe 
phosphoubiquitin accumulation in either 	
S65A/S65A or 	
 knockout 
neurons that was associated with loss of CISD1 substrate ubiquitylation 
(Figure 2). These data support the Parkindependent feedforward model of 
phosphoubiquitin accumulation (Ordureau, Sarraf et al. 2014, Ordureau, Heo 
et al. 2015). Similar findings were recently reported in CRISPR/Cas9 
mediated S65A mutant human embryonic stem (ES) cellderived neurons 
stimulated with A/O in which phosphoubiquitin was not detectable by 
immunoblotting although, the authors were able to detect phosphoubiquitin 
by mass spectrometry (Ordureau, Paulo et al. 2018). To confirm this finding in 
other primary mouse cell types, we exploited a tractable culture paradigm of 
primary adult lung fibroblast mouse cultures (Tian, Azpurua et al. 2013). We 
stimulated adult primary fibroblast cultures from 	
S65A/S65A and 	
 
knockout mice with the protonophore carbonyl cyanide mchlorophenyl 
hydrazone (CCCP) for 18 h which dissipates mitochondrial membrane 
potential similar to A/O. As Parkin protein levels were lower in primary lung 
fibroblasts compared to neurons, we performed an additional mitochondrial 
enrichment step prior to ubiquitin capture by HALOUBAUBQLN1 pulldown. 
Consistent with our results in neurons, we did not observe the accumulation of 
phosphoubiquitin or CISD1 ubiquitylation in both 	
S65A/S65A and 	
 
knockout fibroblasts compared to wildtype cultures (Supplementary Figure 3). 
Overall, our data indicate that phosphorylation of Parkin Ser65 by PINK1 is 
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essential for both activation of its E3 ligase activity and the robust generation 
of phosphoubiquitin in mature mammalian neurons. 
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Since our 	
S65A/S65A mice have been engineered with an inactivating point 
mutation in the endogenous 	
 locus and express comparable levels of 
Parkin protein, we speculated that our model may bypass any epistatic 
compensation induced by the loss of total protein in traditional knockout 
models. We therefore undertook a comprehensive behavioural 
characterisation of our 	
S65A/S65A mice to investigate if loss of 
endogenous Parkin phosphorylation could influence striatal function  . 
Overall, 	
S65A/S65A mice exhibited normal gross development and ageing 
in terms of neurological and behavioural function. We employed the raised 
balance beam as a more sensitive and powerful test of voluntary locomotor 
function, balance and coordinated limb use in our mice. Strikingly, we 
observed that 	
S65A/S65A mice at 12 and 18 months of age exhibited 
consistent impairments in all measures of balance beam performance 
compared to wildtype control mice (Figure 3A). Both the latency to turn 
towards the goal box when placed on the beam end (AGE x GENO: F1,32 
=11.41, <0.01), and the subsequent latency to cross the beam (AGE x 
GENO x SEX: F1,32 =12.82, <0.01) were slower for 	

S65A/S65A mice 
compared to wildtype controls, with mutant males being slower to traverse 
the beam than their female counterparts (Figure 3A). Furthermore, 
quantitation of foot slips while traversing the balance beam demonstrated that 
the number of forelimb (GENO: F1,47 = 29.08, <0.01) or hindlimb (GENO: 
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F1,47 = 38.52, <0.01) slips made by 	

S65A/S65A mice was greater than 
controls (Figure 3A), but this phenotype was not exacerbated at 18 months. In 
addition to deficits in motor function, the impairments observed in 
	
S65A/S65A mice to complete the task, particularly during the “beam turn” 
aspect, could also indicate an underlying, yet subtle defect in cognitive 
planning (Figure 3A). Rotarod testing at 12 and 18 months of age did not 
reveal any substantial differences between 	
S65A/S65A and wildtype mice 
(AGE x GENO: =0.058) (Supplementary Figure 4). Additionally, 	
 
mutant mice did not exhibit any impairments in gait in comparison to wildtype 
mice in terms of stride length and stride width (Supplementary Figure 4).  
Although the rotarod is routinely used to assess locomotor function in rodents, 
its lack of sensitivity and confounding variables are well recognised (Brooks 
and Dunnett 2009). Overall, these data demonstrate that endogenous Parkin 
inactivation  results in selective deficits in a sensitive test of voluntary 
motor function. Consistent with our results, deficits in fine motor coordination 
were reported in one previous report of 	
 knockout mice generated by 
targeted deletion of exon 3 (Goldberg, Fleming et al. 2003) however, in 
another independently generated exon 3 deleted Parkin knockout model, no 
motor deficits were reported although these mice exhibited learning and 
memory deficits (Rial, Castro et al. 2014). More recently, similar fine motor 
deficits were found in 	
 knockout mice in the absence of nigrostriatal 
degenerative pathology (KelmNelson, Brauer et al. 2018), further 
underscoring the importance of performing more sensitive behavioural testing 
in mouse models of PD. In our study we were unable to determine the ageof
onset of the motor deficits, although, it was reported that 	
 knockout mice 
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take approximately 6 months to exhibit detectable locomotor dysfunction 
(KelmNelson, Brauer et al. 2018). 
Given the mitochondrialcentric functions ascribed to the PINK1Parkin dyad, 
we next investigated if the selective motor phenotype in our 	
S65A/S65A 
mice could be attributed to mitochondrial dysfunction. We assayed 
mitochondrial respiration in discrete adult brain regions from 3month old and 
12monthold wildtype and mutant mice using highresolution (Oroboros 
Oxygraph2k) respirometry (Damiano, Gautier et al. 2014). In 3monthold 
mice, we observed no difference in the respiratory control ratio (RCR) defined 
as State3ADP/State4 that reflects mitochondrial oxidative phosphorylation 
coupling efficiency independently of mitochondrial content (Chance and 
Williams 1955, Brand and Nicholls 2011) (Supplementary Figure 5A). In 
contrast we detected a highly selective and consistent difference in 
mitochondrial RCR between the striatum of 12monthold 	
S65A/S65A and 
wildtype mice but not in other brain regions including cortex (Figure 3B and 
Supplementary Figure 5B). This is consistent with previous reports of 
impaired mitochondrial respiration in select brain regions of aged 	
 
knockout mice (Damiano, Gautier et al. 2014), and suggests that ParkinSer65 
phosphorylation contributes to mitochondrial integrity in this brain region. 
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The observed locomotor and striatal mitochondrial dysfunction in 
	
S65A/S65A mice suggested that endogenous Parkin inactivation could also 
negatively impact nigrostriatal integrity . We next performed histological 
analysis of the substantia nigra of aged (~18 months) 	
S65A/S65A and wild
type mice to investigate if impaired viability of nigrostriatal dopaminergic (DA) 
neurons might account for the selective motor defects in 	
S65A/S65A mice. 
Inactivation of endogenous Parkin did not influence striatal anatomy or 
volume in aged mice (Figure 4AC). Nigrostriatal projections are highly 
complex, with a single DA neuron capable of innervating up to 2% of its 
terminal target field (Matsuda, Furuta et al. 2009, McWilliams and Muqit 
2017). Although total DA neuron numbers were comparable between 
	
S65A/S65A mice and controls (data not shown), it is conceivable that 
differences in targetfield arborisation could account for the observed motor 
defect in our mutant animals. At a gross neuroanatomical level, conventional 
chromogenic THimmunohistochemistry revealed indistinguishable striatal 
innervation between genotypes (Figure 4A), however this approach does not 
permit a highresolution analysis of the nigrostriatal projection. To determine if 
	
inactivation could impact the ontogeny and arborisation of DA neurons 
, we employed whole volume imaging of the entire nigrostriatal pathway 
within intact, optically cleared adult brains using iDISCO+ (Renier, Wu et al. 
2014, McWilliams, Prescott et al. 2016, McWilliams, Howard et al. 2017). This 
approach enabled utilization of confocal microscopy to assess the degree of 
innervation and overall connectivity between aged 	
S65A/S65A mice and 
littermate control mice at high resolution. Using this approach, we successfully 
resolved dopaminergic projections in wildtype and 	
S65A/S65A mice, 
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however we observed no differences between groups (Figure 4B). 
Dysfunction in nonneuronal cells is also a reported feature of PDmouse 
models (Vingill, Brockelt et al. 2016). However, immunohistochemical labelling 
of microglia and astroglia by Iba1 and GFAP respectively, revealed no overt 
differences between wildtype and 	
S65A/S65A mice (data not shown). To 
further investigate nigrostriatal function, we next profiled catecholamine 
neurotransmission in our mutant mice. We rapidly dissected striatal tissue 
from agematched wildtype and 	
 littermates and subjected 
these to HPLC analysis. We observed comparable levels of DA and DA 
turnover in wildtype and 	
S65A/S65A striata (Figure 4C), indicating that in 
our mouse model, genetic ablation of endogenous 	
 phosphorylation and 
activation is not sufficient to impact DA neurotransmission . Collectively, 
these data demonstrate that endogenous Parkin inactivation results in a 
selective locomotor defect in the absence of structural nigrostriatal 
dysfunction . Importantly, our findings highlight the importance of Parkin 
activation under steadystate conditions . 
Parkin has received most attention for its role in modulating mitochondrial 
quality control (McWilliams and Muqit 2017). Maximal activation of Parkin E3 
ligase activity leads to ubiquitylation of myriad substrates on the mitochondrial 
outer membrane that engage autophagy receptors and drive the elimination of 
damaged mitochondria  mitophagy (Pickrell and Youle 2015, McWilliams 
and Muqit 2017, Harper, Ordureau et al. 2018). This widely accepted and 
reproducible model is largely based on   findings, however recent 
advances in mouse genetics using the QC and mtKeima reporter 
models have revealed the physiological nature of basal mitophagy  
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(Sun, Yun et al. 2015, McWilliams, Prescott et al. 2016, Kuma, Komatsu et al. 
2017). Furthermore, dopaminergic neurons have recently been shown to 
undergo high levels of mitophagy   which occurs independently of 
PINK1 (Lee, SanchezMartinez et al. 2018, McWilliams, Prescott et al. 2018). 
To investigate the regulation of basal mitophagy in the context of endogenous 
	
 inactivation in mammals, we crossed 	
S65A/S65A mice with the 
QC mitophagy reporter model to generate 	
S65A/S65AQC mice. An 
assessment of wildtype (WT) and S65A QC animals revealed that basal 
mitophagy in nigrostriatal DA cell bodies and projections was indistinguishable 
between wildtype and mutant mice (Figure 4DE). These data reveal that 
nigrostriatal mitophagy is unaffected in a mouse model of endogenous 	
 
inactivation exhibiting selective defects in motor and mitochondrial function.  
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Human patients with 	 mutations typically present with earlyonset PD 
displaying slow progression and sustained response to LDOPA. Mutations in 
several key regulatory residues of Parkin have previously been identified, 
including Cys431Phe which disrupts the catalytic acceptor cysteine within the 
RING2 domain (Maruyama, Ikeuchi et al. 2000). However, to date no 
mutations affecting the Ser65 phosphorylation site have been reported. Here 
we report the first clinical and genetic evidence of PD associated with 
homozygous mutations at p.S65N, the critical node of the PINK1Parkin 
pathway. 
 
Page 16 of 77
http://mc.manuscriptcentral.com/rsob
Submitted to Open Biology: FOR REVIEW ONLY
 


We report a 71yearold Finnish male, diagnosed with earlyonset PD at the 
age of 40 years with no reported family history of Parkinson’s. His 
symptomatic presentation included rigidity of the lower limbs, that was initially 
more marked on the lefthand side, and he exhibited shortness of steps. He 
has continued to experience rigidity throughout his disease course, without 
the development of tremor. Recently, the patient has suffered from a mild gait 
disturbance with occasional freezing and postural instability Overall, the 
progression of his illness has been exceptionally slow with a sustained 
response to medication that currently comprises: Levodopa (300400 
mg/day), Pramipexole (2.1 mg/day) and Selegiline (10 mg/day). On 
examination during the years 201617, he was categorised at stage 2.5 in the 
modified Hoehn and Yahr Scale, with a United Parkinson’s Disease Rating 
Scale (UPDRS) score of 41/199 (Supplementary Table 1) Dopamine 
transporter (DaT) single photon emission computerised tomography (SPECT) 
brain demonstrated reduced density of dopaminergic synaptic terminals in the 
caudate and putamen consistent with degenerative PD (Figure 5A).    
Targeted exome sequencing revealed that the patient carried a novel 
homozygous c.194G>A variant in exon 3 of the 	 gene causing an 
amino acid change p.Ser65Asn (S65N) in the PARKIN protein (Figure 5B).
The variant is very rare: only two heterozygous carriers among 122,271 
subjects were found in the Genome Aggregation Database (gnomAD) with an 
allelic frequency of 8.2x106 In the Exome Aggregation Consortium (ExAC) 
database two heterozygotes were found among 60,691 subjects (allele 
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frequency 1.6x105). Furthermore, the variant site is highly conserved in 
vertebrates (Supplementary Figure 6A)and  analysis of the variant by 
the method of Combined Annotation Dependent Depletion (CADD) (Kircher, 
Witten et al. 2014) predicted that the mutation is deleterious with a CADDC
score of 25.5. We analysed coding variants in 82 selected PDassociated loci 
(Supplementary Table 2) with a CADD Cscore of >20 and population carrier 
frequency <1%, but did not find any other likely pathogenic variant in S65N
M70. 


A 60 yearold Caucasian female diagnosed with PD at the age of 54 was 
identified from the Parkinson’s Progression Markers Initiative (PPMI). Her 
initial clinical features were bradykinesia and gait difficulty on the right side. 
She exhibited characteristic but mild motor symptoms for PD and no atypical 
features have been observed. 12 months following her diagnosis, she was 
commenced on Pramipexole resulting in a positive and sustained response 
(current dosing 2.25mg of Pramipexole/day). At her latest examination, the 
patient was categorized at Stage 2 of the Hoehn and Yahr Scale, and she has 
also been examined using the Unified Parkinson’s Disease Rating Scale 
(MDSUPDRS) for five years (scores from latest examination are provided in 
Supplementary Table 1).  
The patient has also been followed up by DaT imaging for four years, which 
has demonstrated reduced density of dopaminergic synaptic terminals in the 
caudate and putamen consistent with dopaminergic denervation (Striatal 
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Binding Ratio (SBR) calculations from the latest session are provided in 
Supplementary Table 1).  
Genetic analysis of the individual revealed a homozygous Parkin p.S65N 
mutation. Analysis of 82 PDassociated loci revealed three other gene 
variants (in 	 , !" and Glucocerebrosidase ( #$ (Supplementary 
Table 3) that passed our filtering criteria (CADD Cscore >20, carrier 
frequency <1%). A heterozygous recessive variant (p.G268A) in 	 has 
been linked to autosomal recessive/sporadic progressive external 
ophthalmoplegia (PEO) in compound heterozygous or homozygous form (Di 
Fonzo, Bordoni et al. 2003, Graziewicz, Longley et al. 2006), but also 
described as singleheterozygous in a child with a syndrome including 
Parkinsonism born from consanguineous parents (probable autosomal 
recessive mode of inheritance) (Blok, van den Bosch et al. 2009). She also 
carried another 	  variant; a rare inframe deletion 
(exon2:c.153_158del:p.Gln54_Gln55del) in a tandem repeat region of 	  
however, this is likely a benign variant, given a CADD Cscore of 6.2. Overall, 
we did not consider the heterozygous p.G268A 	 mutation as disease
causing in the patient.  A rare heterozygous variant (p.R142H) was detected 
in the !" gene. This gene was initially found to be associated with PD, but 
subsequent studies with large patient cohorts have not supported this finding 
(Flanagan, Healy et al. 2000, Gao, Simon et al. 2009, Dong, Gao et al. 2014, 
Lubbe, EscottPrice et al. 2016). Furthermore, the p.R142H variant has to 
date only been associated with red hair and not PD (Flanagan, Healy et al. 
2000). Thus, we did not consider p.R142H being a diseasecausing variant in 
this patient. In contrast, a heterozygous p.N409S variant in  # was 
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detected, which is a recognised susceptibility factor for PD (Sidransky, Nalls 
et al. 2009) although the variant does not always lead to PD (Gegg and 
Schapira 2018). Therefore we conclude that that the PARKIN p.S65N 
mutation is likely to be the major diseasecausing variant in the patient, 
although we cannot exclude that the GBA p.N409S variant may contribute to 
predisposition and/or the clinical phenotype of the patient. 


+'+
We initially assessed the pathogenicity of the ParkinS65N/S65N mutation 
assaying PINK1Parkin signalling in FlpIn TRex HeLa cells, engineered with 
stable expression of either wildtype Parkin, a nonphosphorylatable S65A 
mutant and the S65N mutant of Parkin. Following the induction of Parkin 
expression, cells were treated with 10 M CCCP or DMSO for 1 or 3 h. 
Immunoblotting of protein extracts demonstrated that the S65N mutation was 
functionally equivalent to the S65A mutation leading to a loss of both Parkin 
activation (as judged by reduced CISD1 and Miro1/2 substrate ubiquitylation), 
and reduced phosphoubiquitin accumulation (Figure 5C). We next 
interrogated the influence of the S65N mutation on endogenous Parkin 
function, by assaying its activity and downstream signalling in patientderived 
cells upon mitochondrial depolarisation. Primary fibroblast cultures were 
established from a skin biopsy of the Finnish patient with homozygous Parkin 
S65N mutation, and an unaffected human control. Cultures were treated with 
10 M CCCP or DMSO for 3 h to induce PINK1 stabilisation and activation 
(Supplementary Figure 6B). Immunoblotting with antiphosphoSer65 Parkin 
antibodies demonstrated that Parkin phosphorylation was abolished in cells 
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expressing S65N (Supplementary Figure 6B). This was associated with 
substantial reduction of Parkin E3 ligase activity as judged directly by 
ubiquitylation of CISD1 in 	%&S65N/S65N fibroblasts (Supplementary Figure 
6B). Furthermore, we observed reduced accumulation of phosphoubiquitin in 
patient fibroblasts compared to control cells, indicating reduced Parkin E3 
ligase activity (Supplementary Figure 6B). We further confirmed loss of Parkin 
E3 activity in patientderived primary cultures by deploying a chemical probe 
that measures transthiolation activity of Parkin  covalent labelling of its 
active site cysteine residue Cys431 (Pao, Stanley et al. 2016). The probe 
revealed robust labelling of activated wildtype human Parkin in control 
fibroblasts, whereas this was completely disrupted in 	%&S65N/S65N mutant 
fibroblasts (Figure 5D). Interestingly upon mitochondrial depolarisation, we 
observed a partial reduction in mitochondrial PINK1 stabilisation in the 
	%&S65N/S65N mutant fibroblasts (Supplementary Figure 7) and this is 
consistent with similar findings observed in CRISPR/Cas9 mediated S65A 
mutant human embryonic stem (ES) cellderived neurons stimulated with A/O 
(Ordureau, Paulo et al. 2018). 
 
We next investigated the effect of the endogenous 	%&S65N/S65N mutation 
on basal and depolarisationinduced mitophagy. We first generated a stable 
mitophagy reporter cell line  retroviral transduction of QC (Allen, Toth 
et al. 2013, McWilliams, Prescott et al. 2018) in both control and 
	%&S65N/S65N patient fibroblast lines. To induce substantial levels of 
mitophagy in culture, patient and control cells expressing QC were 
stimulated with A/O for 24 hours. Upon A/O stimulation, we observed no 
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difference in mitophagy between control and 	%&S65N/S65N QC cells 
(Supplementary Figure 8). These data are consistent with a previous report 
demonstrating that endogenous Parkin is dispensable for basal and 
depolarisationinduced mitophagy in patientderived primary fibroblasts using 
the QC reporter system (Allen, Toth et al. 2013).  

	 
To understand precisely how the pathogenic S65N mutation affects Parkin 
activity, we crystallised and solved the structure of the novel human Parkin 
PD mutant (UBLR0RBR, ∆84143) at 2.9 Å. Comparative analyses of wild
type and ParkinS65N xray crystal structures did not reveal any conformational 
differences between the wildtype and mutant protein (Figure 5E and 
Supplementary Figure 6C), indicating that the S65N mutation does not 
significantly perturb Parkin structure. However, as the S65N mutation 
prevents incorporation of a phosphate group at this position, the absence of a 
negative charge at the UBLIBR interface inhibits the ability of ParkinS65N to 
adopt the open conformation required for full E3 activity. This contrasts to 
wildtype Parkin, where phosphorylation at Ser65 induces key conformational 
changes and new interactions (Wauer, Simicek et al. 2015, Kumar, Chaugule 
et al. 2017, Gladkova, Maslen et al. 2018, Sauve, Sung et al. 2018).
 
.#%#/+
Combining a novel mouse knockin model and unique human clinical case 
studies, we present the most compelling evidence to date demonstrating the 
physiological and clinical significance of PINK1dependent Parkin Ser65 
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phosphorylation. Furthermore, despite over 20 putative substrates reported in 
the literature (Deas, PlunFavreau et al. 2009, Matsuda, Kitagishi et al. 2013), 
our research indicates that inactivation of this PINK1 phosphorylation site on 
Parkin alone is sufficient for humans to develop relatively earlyonset 
Parkinson’s disease (PD).  
 
Understanding the mechanistic basis of dopaminergic (DA) neuronal loss in 
mammalian models of PINK1 and Parkin has proved challenging, since it has 
been difficult to recapitulate a PDlike neurodegenerative phenotype with the 
notable exceptions of mutant 	
 overexpression in mice and rats (Lu, 
Fleming et al. 2009, Van Rompuy, Lobbestael et al. 2014);  the 	
null rat 
model (Dave, De Silva et al. 2014);  and exposure of 	
null mice to 
chronic mitotoxic stress (Pickrell, Huang et al. 2015), Whilst 	
S65A/S65A 
mice have an anatomically intact nigrostriatal pathway with no detectable 
viability, denervation or dopamine depletion even after ageing for 18 months 
(Figure 4A  C), we observed selective locomotor dysfunction particularly on 
balance beam performance (Figure 3A). Our results are consistent with 
previous reports of motor deficits reported in 	
 knockout mice (Goldberg, 
Fleming et al. 2003) and 	
 knockout mice (KelmNelson, Brauer et al. 
2018) in the absence of nigrostriatal pathology.  
The neurobiological basis of the fine motor defects emerging in 	
 and 
	
 genetic models is poorly understood. We did not observe any 
substantial changes in the absolute levels of dopamine in 	
 knockin 
mice. Interestingly, multiple lines of evidence suggest that 	
 KO mice 
exhibit compartment defects with reduced striatal synaptic release of 
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dopamine, associated with reduced expression of both the dopamine 
transporter (DAT) and vesicular monoamine transporter (VMAT2) and higher 
levels of extracellular dopamine in the striatum (Goldberg, Fleming et al. 
2003, Itier, Ibanez et al. 2003). Mild mitochondrial defects have also been 
reported in 24month old 	
 KO mice that are not observed in younger 
mice (9 months of age) (Damiano, Gautier et al. 2014). These effects were 
restricted to the striatum, and not detected in other brain regions including the 
midbrain or cortex (Damiano, Gautier et al. 2014). Using a similar approach, 
our analysis revealed a mild, agedependent defect in mitochondrial 
respiration in the striatum of 	
 knockin mice (Figure 3B). Interestingly, 
this was not associated with any change in basal nigrostriatal mitophagy in 
	
 knockin mice (Figure 4DE). Our current findings are also consistent 
with our recent demonstration of PINK1independent mitophagy   
(McWilliams, Prescott et al. 2018). Recent analysis of '(
melanogaster models expressing fluorescent mitophagy reporters has also 
revealed that basal mitophagy proceeds independently of both PINK1 and 
Parkin   (Lee, SanchezMartinez et al. 2018). Nevertheless, since cell 
culture studies   provide a compelling case for Parkin activation in 
stressevoked mitochondrial quality control pathways (Pickrell and Youle 
2015, McWilliams and Muqit 2017, Harper, Ordureau et al. 2018), it will be 
vital to investigate if nigrostriatal mitophagy is specifically affected in models 
of constitutive mitotoxicity reporting PDrelevant pathology e.g. Polγ mutator 
mouse crossed with 	
 knockout mice (Pickrell, Huang et al. 2015, Sliter, 
Martinez et al. 2018). Ultimately, our findings highlight the importance of 
uncovering the mitophagyindependent pathways by which endogenous 
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Parkin sustains striatal function and mitostasis during ageing. Our data also 
adds to the growing body of evidence that suggests multiple mitophagy 
pathways operate to sustain mitochondrial quality control during specific 
contexts i.e. under basal conditions compared to extreme stress. 
 
At the molecular level, the feedforward mechanism of Parkin activation 
stipulates that (1) PINK1dependent generation of phosphoubiquitin 
stimulates Parkin recruitment to damaged mitochondria, (2) this primes Parkin 
for phosphorylation by PINK1 and thus maximal activation (3) leading to 
further phosphoubiquitin accumulation (Pickrell and Youle 2015, McWilliams 
and Muqit 2017, Harper, Ordureau et al. 2018). Evidence for this model 
includes the demonstration that the Parkin His302Ala (H302A) mutant that 
cannot bind phosphoubiquitin but is catalytically competent, exhibits reduced 
mitochondrial recruitment, Parkin Ser65 phosphorylation, and ubiquitylation of 
substrates in HeLa cells (Kazlauskaite, MartinezTorres et al. 2015, Pao, 
Stanley et al. 2016). However, HeLa studies also suggest that the initial 
amount of phosphoubiquitin generated by PINK1 (independent of Parkin 
activity) is likely to be low since overexpression of the catalytically inactive 
Parkin Cys431Ser mutant does not result in significantly detectable phospho
ubiquitin accumulation (Ordureau, Sarraf et al. 2014, Ordureau, Heo et al. 
2015). Consistent with this latter observation, we did not observe any 
phosphoubiquitin accumulation in mature primary cortical neurons (Figure 2) 
or adult primary lung fibroblasts (Supplementary Figure 3) subjected to 
mitochondrial depolarisation from 	
S65A/S65A and 	
 knockout mice. 
This is consistent with recent analysis of CRISPR/Cas9 mediated S65A 
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mutant human embryonic stem (ES) cellderived neurons stimulated with A/O 
(Ordureau, Paulo et al. 2018). In contrast, we did detect phosphoubiquitin 
accumulation in ParkinS65N mutant patientderived fibroblasts and HeLa cells 
(Figures 5C and Supplementary Figure 6B), albeit at lower levels than wild
type cells, suggesting potential redundancy of Parkin in these cell types with 
both Parkindependent and Parkinindependent formation of phospho
ubiquitin. The MUL1 E3 ligase has recently been reported to operate in a 
parallel pathway to Parkin in nonneuronal cells, and could account for the 
phosphoubiquitin we observe in our human cell systems (Rojansky, Cha et 
al. 2016).  
 
We and others have previously demonstrated that phosphoubiquitin can 
partially activate recombinant nonphosphorylatable Parkin S65A protein 
  (Kazlauskaite, Kelly et al. 2014, Ordureau, Sarraf et al. 2014). Despite 
detectable accumulation of phosphoubiquitin in fibroblasts, we observed 
complete loss of E3 activity in 	%&S65N/S65N mutant cells. The interaction 
affinity between the nonphosphorylated Parkinphosphoubiquitin complex 
with its charged E2~Ub is ~20 fold lower than that for the PhosphoSer65
Parkin and phosphoubiquitin complex (Kumar, Aguirre et al. 2015), which 
may partly explain the lack of activation of  endogenous ParkinS65N (and 
similarly ParkinS65A) protein. Our results therefore highlight the importance of 
studying signalling pathways at endogenous levels in physiologically relevant 
systems. Moreover, our data may also be explained by recent structural 
analysis of Parkin activation mechanisms. Initial binding of phosphoubiquitin 
triggers a conformational shift that exposes a donor ubiquitin binding site and 
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partial activation of Parkin catalytic activity (Kumar, Chaugule et al. 2017). 
The subsequent PINK1dependent phosphorylation of Parkin Ser65 ultimately 
drives Parkin activation by a series of structural alterations. In particular 
displacement of the phosphoUbl domain maintains interaction of the 
ubiquitincharged E2 to the RING1 domain, and the phosphoUbl 
subsequently binds to a basic phosphatebinding site on RING0 (flanked by 
residues Lys161 and Lys211 as well as Arg163) (Wauer, Simicek et al. 2015, 
Gladkova, Maslen et al. 2018, Sauve, Sung et al. 2018). The binding of 
phosphoUbl to RING0 leads to the release of the catalytic RING2 domain 
thereby exposing C431 to promote full Parkin activation and enhancing 
interactions with E2 (Wauer, Simicek et al. 2015, Gladkova, Maslen et al. 
2018, Sauve, Sung et al. 2018). Collectively, our endogenous neuronal results 
combined with recent structural insights highlight the preeminent status of 
Parkin Ser65 phosphorylation in modulating its catalytic activation.  
 
The clinical importance of endogenous PINK1mediated Parkin 
phosphorylation is substantiated by our discovery of two unrelated PD 
patients harbouring novel mutations at Parkin Ser65. Numerically, mutations 
in Parkin are associated with earlyonset PD, accounting for ~40% of cases 
with age of onset below 45 years however, patients with pathogenic Parkin 
inactivating mutations have been reported with midage of onset that would be 
consistent with the second case (Hattori and Mizuno 2017). In line with our 
mouse data, we found that basal and depolarisationinduced mitophagy in 
S65N patientderived primary fibroblasts was not diminished, despite a loss of 
Parkin E3 ligase activity (Supplementary Figure 8). In the future, it will be 
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exciting to address whether this is the case in a more neural context, by 
generating dopamine neurons derived from human induced pluripotent stem 
cells (hiPSCs).  
Although PINK1Parkin signalling constitutes a clear pathway that modulates 
depolarisationinduced mitophagy , basal mitophagy is unaffected both 
	
 KO and 	
 S65A KI mice. Though the clinical significance of 
PINK1Parkin signalling is incontrovertible, the contribution of this pathway to 
mitophagy   remains unclear, as does the contribution of dysregulated 
mitophagy to PD (Jang, Blum et al. 2018). We predict that distinct mitophagy 
pathways orchestrate mitochondrial homeostasis under steadystate and 
stressresponse scenarios. As PINK1Parkin signalling is only disrupted in a 
subset (1015%) of PD patients, it will be important to identify (a) the 
mitophagyindependent functions of this pathway and (b) other mitophagy 
regulators that could be important for regulating nigrostriatal mitochondrial 
homeostasis in idiopathic PD (8085% of clinical cases).  
 
In summary, this study is the first to establish both the physiological and 
clinical significance of PINK1mediated phosphorylation of Parkin at Serine 
65. Our findings shed much needed light on endogenous Parkin function and 
should provoke a reassessment of how it orchestrates cellspecific mitostasis 
.  
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	
S65A/S65A mice were generated by TaconicArtemis GmbH, using a 
targeting strategy to introduce a constitutive knockin of a point mutation (KI
PM) in the 	
 gene by homologous recombination in mouse embryonic 
stem cells. The targeting strategy was based on NCBI transcript 
NM_016694.3. Exon 1 contains the translation initiation codon, and the S65A 
mutation was introduced into exon 3. A positive selection marker (Puromycin 
resistance  PuroR) flanked by FRT sites was inserted into intron 2. The 
targeting vector was generated using BAC clones from the C57BL/6J RPCIB
731 BAC library and transfected into the TaconicArtemis C57BL/6N Tac ES 
cell line. Homologous recombinant clones were isolated using positive and 
negative (Thymidine kinase – TK) selection, and the constitutive KIPM allele 
was obtained after Flpmediated removal of the selection marker. This KIPM 
allele was predicted to express the mutated 	
S65A protein product. The 
remaining recombination site will be located in a nonconserved region of the 
genome. The knockin mice were generated and maintained on an inbred 
C57BL/6J background. Genotyping was performed by endpoint PCR using 
genomic DNA isolated from tails using the following primer sets at an 
annealing temperature of 60°C : Primer 1 
(5’GAACAAGATAGGAGCACAGAAGG 3’) and Primer 2 (5’ 
GACCAATTTACCTCTCGAGTGC 3’) that enabled detection of the wild type 
(290 bp) and S65A KI (365 bp) alleles. The QC mouse model used in 
this study was generated as previously described on a C57BL/6N background 
strain (McWilliams, Prescott et al. 2016) and crossed with 	
 S65A KI 
heterozygote animals to produce homozygous KI animals and wildtype 
littermate controls with endogenous QC reporter.  
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HaloLink resin was purchased from Promega. All mutagenesis was carried 
out using the QuikChange sitedirected mutagenesis method (Stratagene) 
with KOD polymerase (Novagen). All DNA constructs were verified by MRC 
Protein Phosphorylation and Ubiquitylation Unit (PPU) DNA Sequencing 
Service, School of Life Sciences, University of Dundee, using DYEnamic ET 
terminator chemistry (Amersham Biosciences) on Applied Biosystems 
automated DNA sequencers. DNA for bacterial protein expression was 
transformed into ) BL21 DE3 RIL (codon plus) cells (Stratagene). Stock 
solutions of Carbonyl cyanide mchlorophenyl hydrazone (CCCP) (Sigma), 
Antimycin A (Sigma), and Oligomycin (Sigma) were used for experiments in 
cells. Unless otherwise specified, general reagents and chemicals were from 
SigmaAldrich (Merck) and cell culture reagents were from Gibco/Invitrogen 
(Thermo Fisher Scientific). All cDNA plasmids, antibodies and recombinant 
proteins generated in house for this study are available on request through 
our dedicated reagents website: https://mrcppureagents.dundee.ac.uk/ 
 
0 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 
In total 51 	  mice were used for behavioural experiments in 
groups which consisted of 25 wildtype (14 male, 11 female) and 26 
	
S65A/S65A mice  (11 male, 15 female). At 18 months 35 mice remained, 16 
wildtype (10 male and 6 female) and 19 	
S65A/S65A mice (9 male and 10 
female). Mice were housed in sexmatched littermate groups of between 25 
animals per cage with lights adjusted to a 12/12 hour light/dark cycle (lights on 
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at 06.30) and with constant ambient room temperature of 21° ± 1°C.  Animals 
had *+ access to food and water throughout. The mice underwent 
behavioural testing at 12 months and 18 months of age and all experiments 
were conducted in accordance with the 2013 European Union Directive 
2010/63/EU and the UK Animals (Scientific Procedures) Act of 1986 and local 
ethical review at the University of Cardiff. 
The motor test battery has been described previously elsewhere (Brooks, 
Trueman et al. 2012), but briefly mice were tested for simple neurological 
deficits using: clasping and reaching assays; accelerating rotarod and balance 
beam test to measure motor coordination and balance; 30 minute and 24 hour 
open field activity; footprint analysis to measure changes in gait; inverted grid 
task to measure grip strength. For the rotarod test (Ugo Basile, Varese, Italy) 
mice are placed on a rotating beam which accelerates. Initial training 
consisted of training the mice at different speeds for 2 mins (4, 8 and 12RPM). 
Data was collected from 5 sessions at the 12month time point and 2 sessions 
at the 18month time point whereby the mice were placed on the rod that 
accelerated from 440 RPM over 5 mins. The latency of the mice to fall from 
the beam was recorded and used as a measure of motor coordination. For the 
balance beam test (see above reference for dimensions), each mouse was 
trained to run the beam prior to the test session. This consisted of starting the 
mice in the goal box at the top of the inclined beam and over repeated 
exposures moving the starting point on the beam to the lower end (start point) 
such that the mice ran further as the training progressed. Training was 
complete when the mouse was placed on the lower end of the beam (facing 
away from the beam) and the mouse turned and ran the length of the beam 
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unprompted. Footslips were recorded when a foot slipped from the beam 
onto the narrow ledge that ran either side of the length of the beam. Each 
mouse provided data (fore and hind limb footslips, latency to turn and cross 
the beam) from 2 runs for analysis. Gait analysis was run using a footprint test 
whereby the feet of the mice were painted with red (front feet) and blue (rear 
feet) nontoxic waterbased paint and permitted to run a 1 metre corridor that 
was fitted with paper on the floor, such that the mice left coloured paw prints. 
The paw print patterns permit the measurement of variation in gait: stride 
length; base width (distance between left and right front/hind limbs); front/hind 
paw overlap (in normal locomotion the hind paw placement overlaps closely 
with the location where the fore paw had previously landed; gait impairment is 
manifest by an increase in the magnitude and variability of the separation. For 
the motor activity testing using an automated system (Med Associates Inc, 
Vermont, USA), mice were placed in an open field arena for 32 hours with 
free access to food and water throughout. Data was collected automatically 
with activity being measured as the number of infrared beam breaks. Activity 
was measured as the initial 30 minute period (transfer activity) and a 24 hour 
period (3pm3pm) to capture a circadian cycle. In addition, several simple 
behavioural assessments were run: clasping and reaching reflexes where the 
mice is suspended by the tail and lowered to the benchtop with clasping and 
reaching measured through observation and recorded as present or absent; 
Negative geotaxis measures the natural inclination of the mouse to face 
upwards when placed head down on a vertical grid. The mouse is permitted 
30 seconds to correct its orientation to the upright position; Horizontal grid grip 
strength whereby the mice are placed on a flat grid surface which is then 
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rotated 180° along the horizontal axis such the mouse is clinging to the 
underside of the grid. The maximum time for the mouse to remain upturned is 
60 seconds with falling. 
 
,-*(++ 
Parametric splitplot analyses of variance (ANOVA) using age as the within 
groups factor and genotype and sex as between group factors were used 
where applicable as 3way ANOVAs. All statistical analyses were conducted 
on Genstat 17 (VSN International, Hemel Hempstead, UK). Missing values 
were corrected with an inbuilt linear interpolation routine. For nonparametric 
data, χ2 was used to determine significance. Significance level was taken at 
95% confidence.  
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Transcardial perfusion was performed under terminal general anaesthesia to 
obtain tissues for histological analyses. Histology, immunohistochemistry, 
immunocytochemistry & confocal microscopy were performed as previously 
described (BayramWeston, Jones et al. 2012, BayramWeston, Jones et al. 
2016, McWilliams, Prescott et al. 2016, McWilliams, Prescott et al. 2018), with 
minor modifications. Following terminal anaesthesia  intraperitoneal (I.P.) 
administration of Euthatal, adult animals were transcardially perfused with 
PBS to remove excess blood. Tissues were rapidly harvested and processed 
by immersion fixation in freshly prepared 3.7% PFA at pH 7.0 in 0.2M HEPES. 
For QC animals, transverse brain sections (200 mm) were acquired 
using a vibratome (Leica). For chromogenic immunohistochemistry and 
Page 33 of 77
http://mc.manuscriptcentral.com/rsob
Submitted to Open Biology: FOR REVIEW ONLY
 
stereological analyses, coronal brain sections (40 mm) were cut on a sledge 
microtome equipped with a freezing stage (Leitz) and processed for free
floating immunohistochemistry. The following primary antibodies were used: 
Rat monoclonal antilysosomal associated membrane protein 1 (LAMP1) 
(1D4B) (Cat#: sc19992 RRID: AB_2134495  Santa Cruz Biotechnology, 
Inc.); rabbit, sheep and mouse antiTyrosine Hydroxylase (Rabbit: Cat#: 
AB152; RRID: AB_390204; Sheep: Cat#: AB1542; RRID: AB_90755; Mouse: 
Cat#: MAB318; RRID: AB_2201528  Millipore); Rabbit polyclonal antiIonized 
calcium binding adaptor molecule 1 (Iba1) (Cat#: 01919741; RRID: 
AB_839504  Wako). Chicken antiGFP (Cat# GFP1020, 
RRID:AB_10000240 – Aves Labs; Cat# ab13970, RRID:AB_300798 – 
Abcam). AlexaFluor conjugated secondary antibodies were obtained from 
Life Technologies (Molecular Probes/Thermo Fisher Scientific) as described 
previously (McWilliams, Prescott et al. 2018). VECTASHIELD Antifade 
Mounting Medium H1000 was used to mount tissue sections on slides (Leica 
Surgipath). For cell counts and tinctorial histochemistry, Cresyl fast violet 
(Nissl) stain was obtained from Sigma Aldrich (C504210G).  For wholemount 
imaging of the nigrostriatal pathway in intact mouse brains, specimens were 
processed, stained using rabbitTH (AB152) and optically cleared using the 
detailed protocol specified for iDISCO+ (Renier, Wu et al. 2014) 
(https://idisco.info). Following the acquisition of images from intact whole 
brains (dorsal and ventral surfaces), cleared brain specimens were 
hemisected along the midline and subsequently bisected to facilitate deeper 
imaging in the sagittal and coronal planes, respectively. Images were 
acquired using a Zeiss LSM 710 Laser Scanning Microscope (PlanNeofuar 
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340 objective, NA 1.30; Plan Apochromat 363 objective NA 1.4; Plan 
Apochromat 320 objective, NA 0.8), or a Zeiss LSM880 Airyscan Confocal 
Scanning microscope (ZEISS; Plan Apochromat 363 objective, NA 1.4) and 
processed using ZEISS Zen Software/Adobe Photoshop or Imaris (Bitplane) 
for 3D Isosurface Rendering. Images were digitally altered within linear 
parameters, with minimal adjustments to levels and linear contrast applied to 
all images.  
 
6 	
	
	
	

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	 
SemiAutomated Quantitation Images were processed with Volocity 6.3 Image 
Analysis Software (PerkinElmer) using algorithms developed to analyze object 
overlap and count individual structures. For all analyses, we obtained images 
using uniform random sampling by an experimenter blind to all conditions. All 
images in each experimental group were processed as a batch using identical 
protocols. All images were prefiltered to suppress noise (3x3 median filter). 
The same strategy was used to quantify all nonimmunolabelled mitoQC
labelled images using autothresholding to identify objects (mean intensity +3 
standard deviations). Objects were filtered using a minimum size cutoff (0.16 
mm2) and touching objects were separated using a guide size (0.4 mm2). 
Mitolysosomes were typically identified on the basis of thresholded red signal 
not overlapping with green (this condition was relaxed in the case of samples 
where dequenching of the QC probe was observed). Where 
dequenching or spectraloverlap was observed in some instances, we 
employed LAMP1immunohistochemistry to verify the lysosomal nature of 
mitolysosomes and green channel/ combined with LAMP1 immunostaining 
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was used as a proxy for mitolysosomes. In the case of immunolabels used to 
identify cells of interest in brain sections (TH, Iba1), we employed an 
autothresholding criterion of mean intensity +1.5 standard deviations. A 
minimum size of 0.16 mm2 was required, and a "Fill Holes in Objects" 
processing step was applied. Blood vessels were identified on the basis of 
high green channel intensity and distinctive morphology.  
Cell counts were conducted using 2D stereology with an automated stage and 
stereology module “NEWCAST TM” from Visiopharm Integrator System 
software (Visiopharm) on an Olympus Bx50 microscope (Olympus Optical Co. 
Ltd, Tokyo Japan). For NeuN immunohistochemistry, cell counts were 
conducted on a 1:12 series throughout the entire striatum (left and right sides) 
the counting objective set at 100× and the randomised sampling counting 
frame area at 285 ]m2 and corrected using the Abercrombie formula 
(Abercrombie 1946). For the TH and Calbindin double labelling, cell counts 
were carried out on a 1:12 series through the Substantia Nigra with the 
counting objective set at 40x and all visible cells were counted within this area 
with double stained cells denoting A10 dopamine cells and cells only stained 
for TH denoted as A9 dopamine cells.
0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Wildtype and 	
 S65A KI mice (10 per genotype) were killed by 
decapitation without prior anaesthesia. A fragment of the tail was retrieved for 
confirmation of the genotype, determined by PCR amplification, as previously 
described (Fournier, Roux et al. 2013). The brains were rapidly removed and 
the regions of interest (striatum, midbrain and cortex) dissected on ice and 
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weighed. Postnuclear supernatants were obtained by manual 
homogenization of brain samples in 9 volumes of isolation buffer (300 mM 
sucrose, 1 mM EGTA, 5 mM Tris HCl pH 7.4), using a glass Dounce 
homogenizer with a glass pestle, followed by centrifugation at 1000 g, 4°C, for 
10 minutes. The postnuclear supernatants were directly used for respiration 
and protein assays, as well as for the analysis of citrate synthase activity. The 
postnuclear supernatants were analyzed in a thermostaticallycontrolled 
oxygraphic chamber at 25°C with continuous stirring (Oxygraph2k, Oroboros 
instruments, Innsbruck, Austria) as previously described (Damiano, Gautier et 
al. 2014). In brief, the samples were resuspended in 2 ml of mitochondrial 
respiration medium (100 mM KCl, 40 mM sucrose, 10 mM TES, 5 mM MgCl2, 
1 mM EGTA, 0.4% w/v fatty acid freeBSA, pH 7.2) and the protein 
concentration was determined (Bradford protein assay, BioRad). Each 
respiration assay was run with a constant amount of protein from one wild 
type and one knock in mouse (0.3 mg for striatum, 0.6 mg from midbrain and 
cortex). The results were expressed in -. of total protein. The 
respiration rate was recorded sequentially 1) # in the presence 
of complex I substrates (10 mM glutamate, 5 mM malate); 2)  /
 with addition of 1 mM ADP, 3)  0  with 1 ]g/mL 
oligomycin, and 4) !1   was determined by progressive 
additions of 1.25 ]M carbonyl cyanide mchlorophenyl hydrazone (CCCP). 
The ,  , was calculated as Maximal respiration  
Basal respiration.,""was calculated as State 
3/State 4. 
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Citrate synthase (CS) activity was determined using a colorimetric assay 
based on the reaction between 5,5’dithiobis(2nitrobenzoic acid) (DTNB) and 
CoASH to form 5thio2nitrobenzoic acid (TNB), which exhibits maximum 
absorbance at 412 nm, according to the manufacturer’s instructions (Sigma, 
CS0720). In brief, 20 ^L of cold CelLytic M supplemented with protease 
inhibitors (Protease Inhibitor Cocktail, Thermo Scientific 1861279) was added 
to 10 ^L of postnuclear supernatant. The sample was homogenized and 
centrifuged at 12,000 g for 10 min. The supernatant was collected, and 
protein concentration was determined by the Bradford method (BioRad). 
Fifteen to 20 ]g of protein was added to a 200 ^L reaction mixture containing 
1X assay buffer, 300 ^M acetyl CoA and 100 ^M DTNB. The reaction was 
initiated by addition of oxaloacetate (OAA) to a final concentration of 0.5 mM. 
CS activity was evaluated by following the absorbance of the reaction mixture 
at 412 nm (SpectraMax M4) before and after addition of OAA every 10 
seconds, for 2 minutes. Each sample was run in duplicate and CS activity was 
expressed as +.of total protein.  

.	)1&		 
Dopamine and its metabolite 3,4dihydroxyphenylacetic acid (DOPAC) 
concentrations were measured in the dorsal striatum by reverse phase high 
performance liquid chromatography coupled with electrochemical detection 
(Coulochem III, Thermo Scientific) as described earlier (Kilpatrick, Jones et al. 
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1986). Briefly, 18monthold wildtype and 	
S65A/S65A mice were killed by 
cervical dislocation. Brains were quickly removed, precommissural dorsal 
striatum was dissected on an icecold petri dish and freshly homogenized 
in 0.4 M percloric acid. Following centrifugation and filtration of the 
supernatant, dopamine and DOPAC were separated using a C18 reverse 
phase column (Thermo Scientific). The mobile phase consisted of 10% 
acetonitrile, 75 mM NaH2PO4H2O, 0.17 mM octanesulphonic acid, 
2.5 mM triethylamine and 25 mM EDTA, adjusted to pH 3.0 
with orthophosphoric acid and was delivered at a flow rate of 0.6 
ml/min. Protein levels were determined by Lowry assay from pellets of the 
homogenates and catecholamine concentrations are expressed per milligram 
protein.  
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The following primary antibodies were used: total Parkin immunoblotting 
(sc32282, Santa Cruz), mouse Parkin immunoprecipitation (inhouse, S328D, 
5th bleed) βItubulin (Sigma), βactin (Sigma), Calbindin (c9848Sigma), 
GAPDH (Santa Cruz), CISD1 (Proteintech), NeuN (MAB377, Millipore), 
PINK1 immunoblotting (BC100494, Novus), PINK1 immunoprecipitation (in
house S085D, 3rd bleed), Mitofusin2 (MFN2) (inhouse, S781D, 4th bleed), 
OPA1 (#612607, BD Biosciences), RHOT2 (Miro2) (H00089941, Abnova), 
COX IV (#4850, Cell signalling technology), PDH (#2784, Cell signalling 
technology), Tyrosine Hydroxylase (ab112, Abcam), VDAC1 (ab15895, 
Abcam), Vinculin (#4650, Cell signalling technology). Horseradishperoxidase 
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(HRP)conjugated secondary antibodies (Sigma) were used. Anti‐Parkin 
phospho‐Ser65 rabbit monoclonal antibody was raised by Abcam in 
collaboration with the Michael J Fox Foundation for Research. Antiphospho
Ser65ubiquitin rabbit polyclonal antibodies were generated by 21st Century 
Biochemicals Inc. (Marlborough, MA, USA) using two phosphorylated 
peptides CAhxYNIQKE[pS]TLHLVLamide and AcYNIQKE[pS]TLHLVL
AhxCamide that correspond to amino acid residues 59 – 71 of ubiquitin. 
Antibodies were affinity purified using phosphorylated and non
phosphorylated versions of the peptide immunogen (Supplementary Figure 
9A). A fragment of human Miro1 fusion protein encompassing residues 1 592 
with Nterminal HisSUMO tag was used as an immunogen to raise a sheep 
polyclonal antiMiro1 antibody (S531D). Antibodies were affinity purified from 
antisera and characterised indicating crossreactivity with Miro1/2 as 
described in Supplementary Figure 9B. 
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FlpIn TRex HeLa stable cell lines were cultured in DMEM (Dulbecco’s 
modified Eagle’s medium) supplemented with 10 % FBS (foetal bovine 
serum), 2 mM LGlutamine, 1X Pen/Strep, 1X nonessential amino acids (Life 
Technologies), 15 g/ml of Blasticidin and 100 g/ml of Hygromycin. Cell 
transfections of untagged wildtype or mutant Parkin were performed using 
polyethylene method (Reed, Staley et al. 2006). Cultures were induced to 
express protein by addition of 0.1 g/ml of Doxycycline to the medium for 24 
h. To depolarise or uncouple mitochondrial membrane potential, proliferating 
cells were treated with 10 ^M Antimycin (Sigma) and 1 ^M Oligomycin 
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dissolved in DMSO. Primary mouse cortical neurons were isolated from the 
brains of wildtype or mutant embryos of either sex at E16.5. Embryonic 
cortices were collected in HBSS, and cells were dissociated by incubation 
with TrypsinEDTA (#25300054, Gibco) at 37°C. Cells were then diluted in 
Neurobasal medium containing B27 supplement, Glutamax, 
penicillin/streptomycin and plated at a density of 6.0 × 106 cells/well on 6well 
plates coated with 0.1 mg/ml polyLlysine (PLL; Sigma). Neurons were 
cultured at 37°C in a humidified incubator with 5% CO2. Every 7 days, the 
medium was replaced with fresh medium containing B27. To depolarise or 
uncouple mitochondrial membrane potential in neurons, cultures were treated 
with 10 ^M Antimycin (Sigma) and 1 ^M Oligomycin dissolved in DMSO at 
37°C.  
 
Primary lung fibroblasts were derived from adult mice as previously described 
and maintained in DMEM/20%FBS/penicillinstreptomycin at 37°C/5% CO2 
(Tian, Azpurua et al. 2013).  Primary human skin fibroblast cultures at low 
passage from the patient and one matched control were established from a 
minimally invasive skin biopsy sample according to routine culture 
procedures. The cells were cultured in 5% CO2 and 90% humidity in high
glucose DMEM media (Gibco) supplemented with 10% FBS (LSP #S001
BR), 1x nonessential amino acids, 1 mM Sodium Pyruvate, 100 Units/ml 
penicillin, 100 ]g/ml streptomycin and 2 mM LGlutamine.. The retrovirus for 
analysis of mito2" in human fibroblasts was generated as previously 
described (Allen, Toth et al. 2013). The cDNA for the mito2" reporter 
[mCherry, GFP and residues 101–152 of human FIS1] was cloned into a 
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pBABE.hygro vector or pBABE.puro vector. The construct was cotransfected 
into 293FT cells with GAG/POL and VSVG expression plasmids (Clontech, 
SaintGermainenLaye, France) for retrovirus production using Lipofectamine 
2000 (Life Technologies) in accordance with manufacturer’s instructions. 
Virus was harvested 48 h after transfection and applied to cells in the 
presence of 10 mg/ml polybrene. Cells were selected with either 500 ^g/ml of 
Hygromycin B or 2 ^g/ml Puromycin. Selected cells were seeded and 
incubated for 24h into glass bottom dishes (Ibidi ^Dish 35 mm) with media 
free of Sodium pyruvate and nonessential amino acids. Mitophagy was 
stimulated for 24h with 10 ^M Antimycin A (Sigma #A8674) and 5 ^M 
Oligomycin A (Sigma #75251), and controls were treated at equal volumes of 
DMSO. Cells were fixed for 20 min with 3.7% PFA (Sigma #P6148) pH 7.0 
and subsequently washed twice with 2 ml of DMEM + 10 mM HEPES pH 7.0 
and incubated for at least 10 min. Images were acquired using ZEISS LSM 
710 confocal microscope and quantified using Volocity 6.3 Image analysis 
software as previous described (McWilliams, Prescott et al. 2018).   
 
" 	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For analysis of endogenous Parkin protein expression  , fresh brains 
were rapidly excised, placed in cold PBS and microdissected with ultrafine 
microknives under stereomicroscopy. Upon isolation, each brain region was 
collected in a single 1.5 ml microcentrifuge tube and immediately plunged into 
dry ice. Tissue samples were stored at 80°C until ready for processing. To 
make protein extracts, all tissues (neural subregions and extraneural tissues) 
were weighed and defrosted on wet ice in 5fold mass excess of freshly 
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prepared, icecold lysis buffer containing: 50 mM Tris/HCl, pH 7.5, 1 mM 
EDTA pH 8.0, 1 mM EGTA pH 8.0, 1% Triton X100, 0.25 M sucrose, 150 mM 
NaCl, 2 mM sodium orthovanadate, 1 mM NaF, 10 mM Sodium 
glycerolphosphate, 1.15 mM Sodium Molybdate, 4 mM Sodium tartrate 
dehydrate, 100 mM 2Chloroacetamide, 1 mM DTT and Complete protease 
inhibitor cocktail (Roche). All inhibitors and DTT were added immediately prior 
to use. Tissue homogenisation was performed using a probe sonicator at 4°C 
(Branson Instruments). Crude lysates were incubated at 4°C on wet ice for 
3045 min, before clarification by centrifugation at 14,000 rpm for 30 min at 
4°C. Supernatants used for subsequent steps were carefully removed and 
either used for downstream biochemical analyses or snapfrozen and stored 
at 80°C.  
Primary neurons or Hela cells were sonicated in lysis buffer containing 50 mM 
Tris–HCl (pH 7.5), 1 mM EDTA, 1 mM EGTA, 1% (w/v) Triton, 1 mM sodium 
orthovanadate, 10 mM sodium glycerophosphate, 50 mM sodium fluoride, 
10 mM sodium pyrophosphate, 0.25 M sucrose, 1 mM benzamidine, 0.1 mM 
PMSF and protease inhibitor cocktail (Roche). Following the sonication, 
lysates were incubated for 30 min on ice. Samples were spun at 20,800 x . in 
an Eppendorf 5417R centrifuge for 30 min. Supernatants were collected and 
protein concentration was determined using the Bradford kit (Pierce). Primary 
human skin fibroblasts were lysed with icecold lysis buffer containing 50 mM 
TrisHCl pH 7.5, 1% (v/v) Triton X100, 1 mM EGTA, 1 mM sodium 
orthovanadate, 50 mM sodium fluoride, 10 mM βglycerophosphate, 5 mM 
sodium pyrophosphate, 0.1 g/mL MicrocystinLR (Enzo Life Sciences), 270 
mM Sucrose, complete EDTAfree protease inhibitor cocktail (Sigma Aldrich 
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Cat # 11836170001). Lysates were centrifuged at 20 800x . for 10 min at 
4°C. Supernatants were collected, quantified by Bradford assay (Thermo 
Scientific) and subjected to immunoblot analysis. 
 
0)		
)
 
Cells were collected in icecold PBS containing 200 mM chloroacetamide. 
They were then lysed in buffer containing 250 mM sucrose, 20 mM HEPES, 3 
mM EDTA, 1 % (w/v) 1 mM sodium orthovanadate, 10 mM sodium β
glycerophosphate, 50 mM NaF, 5 mM sodium pyrophosphate, pH 7.5 and 
protease inhibitor cocktail (Roche) supplemented with 100 mM 
chloroacetamide at 4 °C. Cells were disrupted using a glass handheld 
homogenizer (40 passes) and the lysates were clarified by centrifugation (800 
x . at 4°C for 10 min). The supernatant was harvested and subjected to an 
additional centrifugation step at 16,600 x . for 10 min at 4 °C. The resulting 
pellet containing the mitochondrialenriched fraction was resuspended in the 
above buffer containing 1 % Triton X100 and centrifuged at 13,000 . for 
10 min at 4 °C. The supernatant arising from this step contained solubilised 
mitochondrial proteins.  

#)) 

!	)) 
	
 
For immunoprecipitation of endogenous PINK1 from human skin fibroblasts, 
150 ^g of whole cell lysate was incubated overnight at 4°C  with 5 ^g of 
protein G prebound to PINK1 antibody. The immunoprecipitations were 
washed four times with lysis buffer containing 150 mM NaCl, then twice with 
buffer containing 50mM Tris HCl pH 7.5, 0.1 mM EGTA, and eluted by 
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resuspending in 20 ^L of 1X SDS sample buffer. Denatured samples were 
subjected to SDSPAGE (4–12% BisTris gels) and were transferred on to 
Protran 0.2 NC nitrocellulose membranes (Amersham). Membranes were 
blocked for 1 h at room temperature with 5% nonfat milk (Marvel) or bovine 
serum albumin (BSA) in TBST [Trisbuffered saline (50 mM Tris/HCl and 150 
mM NaCl, pH 7.5) containing 0.1% Tween20] in phosphate buffered saline 
(PBS) pH 7.4 and incubated with the indicated antibodies overnight at 4°C 
with agitation. Detection was performed using HRPconjugated secondary 
antibodies (Goat antiRabbit IgG (H+L) Secondary Antibody, HRP conjugate 
, #31460, Thermo Scientific; Rabbit antiMouse IgG (H+L) Secondary 
Antibody, HRP conjugate, #31450, Thermo Scientific;  Rabbit antiSheep IgG 
(H+L) Secondary Antibody, HRP conjugate, #31480, Thermo Scientific). 
Membranes were developed using standard chemiluminescence with ECL 
(Amersham) and exposure to hyperfilm (GE Healthcare). 
 


(	!	7  
Transthiolation activity of Parkin activity in primary human skin fibroblasts was 
measured as described previously (Pao, Stanley et al. 2016). Briefly, Parkin 
probe (produced by Dr. Satpal Virdee, MRC PPU) was added to 50 ^g of 
whole cell lysate at a final concentration of 5 ^M. Reactions were incubated at 
30°C for 4 h and quenched by the addition of LDS sample buffer with β
mercaptoethanol, before analysis  SDSPAGE (412% BisTris Gels, 
Novex) and immunoblotting as previously described.  
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HisHaloUbiquilin UBAdomain tetramer (HALOUBAUBQLN1) was expressed 
in ) BL21 cells, affinity purified on NiNTAagarose and dialysed into 50 
mM HEPES pH 7.5, 10 % glycerol, 150 mM NaCl, 1 mM DTT (Kazlauskaite, 
MartinezTorres et al. 2015).  For ubiquitin capture, 200400 ^g of whole cell 
extract or 1 mg of membraneenriched fraction was used for pull down with 
HALOUBAUBQLN1 (Kazlauskaite, MartinezTorres et al. 2015). HALO
UBAUBQLN1 was incubated with 200 ^l of HaloLink resin (Promega) in binding 
buffer (50 mM TrisHCl [pH 7.5], 150 mM NaCl, 0.05% NP40) overnight at 
4°C under agitation (Kazlauskaite, MartinezTorres et al. 2015). HALOTUBE 
beads (20 ^l) were added to lysates and incubated for at 4°C for 4h under 
agitation. Beads were washed three times with lysis buffer containing 0.25 M 
NaCl, and eluted by resuspending in 20 ^l of 1× LDS sample buffer containing 
1mM DTT. 
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Parkin S65N (ParkinS65N) (∆84143) was cloned into pET156P vector 
(DU56345) and expressed as HisSUMO fusion in )  BL21 cells, using 
conditions similar those described in (Chaugule, Burchell et al. 2011). His
tagged ParkinS65N was purified using NiNTA resin. Protein eluted from Ni 
resin was incubated overnight at 4°C with SENP1 protease to remove the His
SUMO tag, and dialysed in 20mM Tris pH 7.5, 75mM NaCl and 250 ^M TCEP 
buffer. Dialysed protein was further incubated with NiNTA resin and tagfree 
ParkinS65N was collected in the flow through, purified on MonoQ and 
Superdex75 columns (as described in (Kumar, Aguirre et al. 2015)) and 
concentrated to 8 mg/ml for crystallisation. ParkinS65N was crystallised at 4°C 
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in 100mM BISTRIS pH 5.5, 200mM LiSO4 and 20% PEG3350 by using a 
vapour diffusion method under sitting drop. Crystals were flash frozen in 20% 
glycerol, native data set was collected at ID30A1 beamline, European 
Synchrotron Radiation Facility (ESRF, Grenoble). Data was processed using 
Mosflm and Aimless in CCP4 (CCP4, 1994). ParkinS65N structure was 
determined by molecular replacement using Phaser in CCP4, WTParkin (pdb 
id: 5C1Z) was used as the search model. The initial model obtained from 
Phaser was further constructed and refined using Coot (Emsley and Cowtan 
2004) and REFMAC5 in CCP4 (Murshudov, Skubak et al. 2011), respectively. 
The final model of ParkinS65N shows excellent geometry (Supplementary 
Table 4). 
 
1 )	2
	 
"+(09:;
Patient DNA samples were screened for variants using HaloPlex targeted 
sequencing of 82 selected PDassociated loci (Agilent Technologies, Santa 
Clara, CA, USA). DNA was extracted from peripheral blood by standard 
procedures. Sequencing was performed with MiSeq sequencer (Illumina, San 
Diego, CA, USA), variant calling with Genome Analysis Toolkit (McKenna, 
Hanna et al. 2010) and the annotation with ANNOVAR (Wang, Li et al. 2010). 
The variants were confirmed by independent DNA sequencing method, 
Sanger sequencing. For the c.194G>A mutation in 	 we used the 
following PCR and sequencing primers for PCR and sequencing: 5’
CTCGCATTTCATGTTTGACATTTCC; 5’
ATGCTCCATGCAGACTGCACTAAAG; sequencing 5’
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CCTGCTGTCAGTGTGCAGAATG. The frequency of variants was screened 
from Exome Aggregation Consortium (ExAC) browser 
(http://exac.broadinstitute.org/) and  gnomAD browsers 
(http://gnomad.broadinstitute.org)  (Lek, Karczewski et al. 2016), the potential 
pathogenic effects were evaluated using CADD Cscore (Kircher, Witten et al. 
2014) and conservation using UniProt (Apweiler, Bairoch et al. 2004). 
<+(=:;
We downloaded the clinical data of case 2 (ID 3185) from the Parkinson’s 
Progression Markers Initiative (PPMI) database (www.ppmiinfo.org/data) on 
August 13, 2018. PPMI is a multicenter, ongoing longitudinal and 
observational study, which contains clinical, imaging and biological data from 
454 PD patients and 215 control patients currently stored at the Laboratory of 
Neuro Imaging (LONI) database at University of California, Los Angles 
(UCLA). The cohort consist of 620 females and 828 males. The openaccess 
repository is available online after registration at http://www.ppmiinfo.org/.
Informed consent was signed by the patients enrolled in the PPMI study. The 
patient’s DNA whole genome sequence data was downloaded  from PPMI 
repository on Sept 811th, 2018 and we filtered all coding variants in 82 PD
associated loci (used intargeted sequencing panel of patient S65NM70 
(ID3185) excluding mitochondrial DNA) with a CADD Cscore of over 20 and 
a carrier frequency <1%. Polyphen2 (Adzhubei, Schmidt et al. 2010) HVAR
based predictions are provided for each variant. 
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7 Depiction of targeting strategy to generate a constitutive knockin of 
Ser65Ala (S65A) point mutation in the !+ +++ 	
 (Parkin) gene 
(targeting strategy based on NCBI transcript NM_016694.3). Exon 1 contains 
the translation initiation codon. The S65A mutation was introduced into exon 
3. The 	
S65A/S65A knockin allele was generated following Flpmediated 
recombination. 37 Rostrocaudal expression analysis of Parkin protein 
expression in the mouse central nervous system (CNS) under basal 
conditions. Immunoblot analysis of subdissected CNS regions from adult 
wildtype and 	
S65A/S65A mice. OB, olfactory bulb; CTX, neocortex; THAL, 
thalamus; STR, striatum; HC, hippocampus; VM, ventral midbrain; CB, 
cerebellum; BSt (brainstem) and SPc (spinal cord). 7 Parkin Ser65 
phosphorylation is essential for Parkin activation in primary neurons. Mature 
(21 DIV) primary cortical neuron cultures were established from wildtype and 
	
S65A/S65A mice, and stimulated for 3 h with a combination of Antimycin A 
(10M)/Oligomycin (1M). Whole cell extracts were subjected to SDSPAGE 
and immunoblot analysis with antiParkin, antiphosphoSer65 Parkin, anti
CISD1 and βIII tubulin antibodies.  
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Immunoblots showing comparative analysis of phosphoSer65 ubiquitin levels 
in mature (21 DIV) primary cortical neuron cultures from the following groups: 
	
S65A/S65A mice and matched wildtype controls; 	
 knockout (KO) and 
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wildtype mice and 	
 knockout and wildtype mice. Cultures were 
stimulated with A/O for 3 h before lysis and membrane enrichment. Protein 
extracts were enriched for ubiquitylated substrates by incubating with 
ubiquitinbinding resin derived from HisHaloUbiquilin UBAdomain tetramer 
(HALOUBAUBQLN1). Enriched lysates were subjected to immunoblotting with 
antiphosphoSer65 ubiquitin and CISD1 antibodies. 
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7 Balance beam performance in 	
S65A/S65A and wildtype mice at 12 
months and 18 months of age. Animals were assessed by their ability to reach 
a platform by competently traversing a raised and tapered beam. 
Performance was recording the number of errors scored as slips (forelimb, 
hindlimb and combined). 	
S65A/S65A mice made significantly more forelimb 
errors and hindlimb errors at 12 and 18 months (<0.01) than their WT 
littermates. The 	
S65A/S65A mice also demonstrated an agerelated decline 
in their ability to orientate themselves on the beam end and cross the beam 
resulting in longer latencies on both measures compared to WT littermates 
(<0.01). Error bars represent the standard error of the mean. 3Striatal RCR 
is affected in 	
S65A/S65A mice.Mitochondrial respiratory acceptor control 
ratios in the striatum, midbrain, and cortex of 1year old aged wildtype and 
	
S65A/S65A mice (=10 per group).
 
=! @7	')
*
!
	
	!	

Page 50 of 77
http://mc.manuscriptcentral.com/rsob
Submitted to Open Biology: FOR REVIEW ONLY
 
(7 Striatal innervation is indistinguishable between wildtype and 
	
S65A/S65A (KI) mice. 7No differences were observed by antiTyrosine 
Hydroxylase (TH) based immunohistochemistry analysis of midbrain and 
striatum between genotypes. 37 Striatal innervation analysis of THpositive 
DA neurons within intact brains processed by iDISCO+. Arborisation of DA 
neurons is indistinguishable between wildtype and KI mice. 7No differences 
were observed in striatal volume between genotypes. Error bars represent 
standard errors of the mean. Striatal dopamine levels are unaltered in 
	
S65A/S65A mice. HPLC analysis revealed no differences in DA and 3,4
dihydroxyphenylacetic acid (DOPAC) levels between wildtype and KI mice 
(=10 per genotype). Data represent mean values, ±SEM. .. Basal 
mitophagy is unaltered by endogenous Parkin activation . Maximum z
projections of midbrain DA neurons from QC wildtype and KI mice 
immunolabelled with antibodies to TH (blue) and LAMP1 (grayscale).Arrows 
point to mitochondria and arrowheads point to  mitochondria associated with 
(autophago)lysosomes/mitolysosomes as defined by colocalisation of LAMP1 
and QC staining. Mitochondrial delivery to lysosomes is associated with 
quenching of GFP signal of the QC reporter and residual mCherry only 
signal intensity. Scale bar 5 m. $. Quantitation revealed no differences 
between mitophagy in DA cell bodies or axons. Results are expressed as 
mean values ±SEM. *=<0.05; ns=not significant.
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7Dopamine transporter imaging (DaT scan) results with semiquantification 
by region. 123IFPCIT brain singlephoton emission computed tomography 
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(SPECT) or DaT scan imaging measure dopamine transporter density in 
presynaptic terminals of the dopaminergic neurons projecting from the 
substantia nigra to dorsal striatum (caudate nucleus and putamen) thereby 
enabling assessment of the structural integrity of the nigrostriatal pathway in 
humans. DaT SPECT imaging was performed three hours after an 
intravenous injection of 186 MBq 123IFPCIT using a double head gamma 
camera with a fan beam collimator. Thyroidal uptake was blocked by 300 mg 
of oral potassium perchlorate before the tracer injection. Occipital lobe was 
used as a reference region of nonspecific binding. The Zscores in the top 
right of the figure indicate significant deviation from the population mean 
values for both the left and right caudate and putamen. In the putamen, the 
dopamine transporter density was slightly more reduced, which is typical of 
the rostrocaudal pattern of uptake loss in PD. 37 Electropherogram detailing 
S65N mutation data (Exon 3 G>A) 7Parkin S65A and S65N mutants display 
reduced Parkin activation in response to PINK1 activation. FlpIn TRexHeLa 
cells stably expressing wildtype (WT), S65A and S65N Parkin were induced 
with 0.1 g/ml doxycycline for 24 h prior to stimulation with DMSO or 10 M 
CCCP at indicated timepoints (1 hour or 3 hours). Whole cell lysates were 
subjected to immunoblot analysis using the indicated antibodies. For detection 
of ubiquitylation (marked by open circles), lysates were subjected to 
ubiquitylatedprotein capture by HisHaloUbiquilin1 UBAdomain tetramer 
(HALOUBAUBQLN1), prior to immunoblot with antiCISD1 (Proteintech Europe) 
and antiMiro1/2 (DSTT, S531D 5th bleed). .7 Activitybased profiling of 
Parkinson’s disease associated Parkin S65N patientderived fibroblasts. 
Primary fibroblasts derived from skin biopsies from a healthy subject (WT) 
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and a PD patient harbouring a Parkin S65N homozygous mutation were 
profiled with E2Ubiquitinbased probe to monitor Parkin E3 transthiolation 
activity as described previously (Pao, Stanley et al. 2016). Parkin S65N 
patient cells cannot be activated following CCCP treatment (3 h, 10 M). $7
Composite schematic illustrating the xray crystal structure of the Parkin S65N 
diseasemutant, superimposed over the wildtype structure (PDB ID: 5C1Z, 
Grey)7 ParkinS65N structure is depicted in colour: UBL (teal), RING0 
(magenta), RING1 (orange), IBR (blue), REP (yellow) and RING2/Rcat (red).  
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Parkin protein expression in peripheral 
tissues under basal conditions. Lung, spleen, pancreas, and heart extracts 
from adult wildtype, 	
S65A/S65A mice and 	
 knockoutmice (heart) 
were immunoprecipitated with antiParkin sheep polyclonal antibody (in
house, DSTT S328D) and subjected to immunoblot analysis with antiParkin 
mouse monoclonal antibody (Santa Cruz).  
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 7Mature (21 DIV) primary cortical 
neuron cultures were established from C57/BL6J mice, and stimulated for 5 h 
with a combination of Antimycin A (10M)/Oligomycin (1M). Membrane
enriched extracts were enriched for ubiquitylated substrates by incubating 
with ubiquitinbinding resin derived from HisHaloUbiquilin UBAdomain 
tetramer (HALOUBAUBQLN1), and subjected to immunoblotting with SDS
PAGE and immunoblot analysis with antiphosphoSer65 ubiquitin, anti
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CISD1, antiVDAC1, antiMitofusin2 (MFN2), and antiRHOT2 (Miro2) 
antibodies. MemCode indicates equivalent loading for TUBE pulldowns. 
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Comparative analysis of phosphoSer65 ubiquitin in adult lung fibroblast 
cultures from the following groups: 	
S65A/S65A mice and matched wildtype 
controls; and 	
 knockout (KO) and matched wildtype mice. Cultures were 
stimulated with CCCP (10 M) for 18 h before lysis and membrane 
enrichment. Protein extracts were enriched for ubiquitylated substrates by 
incubating with ubiquitinbinding resin derived from HisHaloUbiquilin1 UBA
domain tetramer (HALOUBAUBQLN1). Captured proteins were subjected to 
immunoblotting with antiphosphoSer65 ubiquitin and CISD1 antibodies.  
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7 No 
significant differences were found between WT and ParkinS65A/S65A mice on 
rotarod performance or with gait analysis.  

 )
	=! 70
			
	!
	
!
)7 
7 Normal mitochondrial respiration in 3month old 	
S65A/S65A mice.
Mitochondrial respiratory acceptor control ratios in the striatum, midbrain, and 
cortex of 3month old wildtype and 	
S65A/S65A mice (=10 per group). 37 
Paired analysis of 1year old aged mice mitochondrial respiratory acceptor 
control ratio in the Striatum performed on consecutive days.  
Page 54 of 77
http://mc.manuscriptcentral.com/rsob
Submitted to Open Biology: FOR REVIEW ONLY
 
 
 )
	 =!  7 = 
	 		  	, 	
		
	+) 
	
7 
7Multiple sequence alignment of Ser65 residue in human Parkin and other 
organisms. 37 Parkin phosphorylation and activity is abolished in S65N 
patientderived fibroblasts7 Primary fibroblast cultures established from skin 
biopsies from a healthy subject (	%&WT) and a PD patient harbouring a 
ParkinS65N homozygous mutation (	%&S65N) were profiled after 
treatment with DMSO or CCCP (3hours, 10 M). Lysates were subjected to 
immunoblot analysis using the indicated antibodies. Ubiquitincapture was 
used prior to immunoblotting with antiCISD1 and antiUBpS65. Endogenous 
PINK1 was detected after immunoprecipitation from 150 g whole cell lysate. 
Representative of 3 experiments. 7 Electron density map of residues 
surrounding Asn65 in UBL domain of Parkin. 
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7 Mitochondrial fractions were prepared from 
primary fibroblasts isolated from a healthy subject (HF WT) and a PD patient 
harbouring a ParkinS65N compound heterozygous mutation (HF S65N) 
treated with DMSO or 10 M Antimycin A /1 M Oligomycin (A/O). PINK1 was 
detected after immunoprecipitation from 100 g of mitochondrial fraction.
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7 Isolated primary human skin fibroblast cultures were transduced with 
retroviral 2" reporter and stimulated with DMSO (Control) and 10 M 
Antimycin A /5 M Oligomycin (A/O) for 24 hours. Cultured cells were then 
fixed and mitophagy (mCherryonly mitolysosomes) was visualized by 
confocal microscopy. Scale bar 10 m. (Inset: arrowheads indicate 
mitolysosomes) 3 Mitophagy was readily observed under A/O conditions in 
both Parkin WT and S65N fibroblasts, however, there was no significant 
difference between genotypes (Twoway ANOVA: **=	<0.01; Bonferroni post
test for DMSO vs. A/O in WT (*=	<0.05) & S65N (***=	<0.001), and n.s. for 
WT vs. S65N with A/O or DMSO).  
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7 Characterisation of antiPhosphoSer65 Ubiquitin antibody. Titration of 
increasing concentrations (1000ng, 300ng, 100ng, 30ng,10ng, 3ng and 1ng) 
of recombinantly expressed fulllength pSer65Ub, Ub or a synthesised 
peptide of pSer57Ub. The antibody specificity towards pSer65Parkin was 
analysed using a titration of 70% pSer65Parkin. Recombinant phospho
proteins or ubiquitin were subjected to SDSPAGE and immunoblot analysis.
37 Characterisation of antiMiro1/2 antibody (host: sheep, S531D) raised 
against human HisSUMO Miro1 residues (1592).  Domain architecture of 
human Miro1 (EF: EFhand motive, TM: Transmembrane domain) and the 
region against which the antibody was raised. 3: HEK293 cells transfected 
with human or mouse HAMiro1 or HAMiro2 were lysed and indicated 
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amounts of whole cell extracts were subjected to SDSPAGE and immunoblot 
analysis for all five bleeds. 
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All animal studies and breeding in Dundee was approved by the University of 
Dundee ethical review committee, and further subjected to approved study 
plans by the Named Veterinary Surgeon and Compliance Officer (Dr. Ngaire 
Dennison) and performed under a UK Home Office project license in 
accordance with the Animal Scientific Procedures Act (ASPA, 1986). 
Associated collaborative institutes which contributed to the present study 
(mouse behaviour and histology  Cardiff University, UK; mitochondrial 
respiration analyses – CNRS, Paris, FR) also received institutional ethical 
approval.  
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Informed consent was obtained from the patient. Ethical approval for the study 
(Dnro 432/E9/07) was given by the Ethics Review Board of Helsinki University 
Central Hospital. We used UPDRS and Modified Hoehn and Yahr scales to 
evaluate current progression of the disease. Informed consent was signed by 
the patients enrolled in the PPMI study. The authors have agreed to PPMI 
Data Use Agreement. The manuscript was reviewed by PPMI Data & 
Publications Committee (DPC) prior to submission. 
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Coordinates and structure factors have been deposited with the PDB 
database (PDB ID 6HUE). 
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